A drug developed for one problem sometimes solves others
Uma classe de medicamentos que entrou no imaginário popular como solução para o excesso de peso começa a revelar uma vocação muito mais ampla. No Brasil, a Anvisa acaba de autorizar o uso de Wegovy para uma doença hepática grave, enquanto pesquisadores investigam se as mesmas moléculas podem tratar dependência de álcool e doenças neurodegenerativas. O que parecia um atalho para a magreza se transforma, aos poucos, em uma nova linguagem para compreender a inflamação, o metabolismo e a fragilidade do cérebro humano.
- A Anvisa aprovou o Wegovy para tratar doença hepática gordurosa metabólica com fibrose moderada a avançada — uma condição séria que, sem intervenção, pode evoluir para cirrose irreversível.
- Ozempic e Mounjaro já atuam no diabetes tipo 2, e o Mounjaro ganhou aprovação para apneia obstrutiva do sono em pacientes obesos, sinalizando que essas drogas cruzam fronteiras entre especialidades médicas.
- Um estudo publicado na Nature Communications aponta redução de 50 a 56% na ocorrência e recorrência do transtorno por uso de álcool com semaglutida — uma descoberta que pode transformar um campo terapêutico historicamente limitado.
- Pesquisadores da UERJ investigam o potencial da tirzepatida contra a neuroinflamação, enquanto a liraglutida já demonstrou desacelerar o declínio cognitivo em 18% e reduzir a atrofia cerebral em quase 50% em pacientes com Alzheimer inicial.
- O que emerge não é apenas um novo uso para velhos remédios, mas uma revisão profunda do que essas moléculas tocam: inflamação, função neurológica e a capacidade do cérebro de se preservar.
A Anvisa ampliou silenciosamente o alcance dos injetáveis de emagrecimento. O Wegovy, caneta que se tornou símbolo da perda de peso rápida, acaba de receber aprovação para tratar a doença hepática gordurosa metabólica associada à disfunção metabólica — conhecida como MASH — em adultos com fibrose moderada a avançada, antes que o dano se torne irreversível com a cirrose.
O Wegovy não está sozinho nessa expansão. O Ozempic, que compartilha a semaglutida como princípio ativo, já é prescrito há tempos para diabetes tipo 2. O Mounjaro, baseado na tirzepatida, faz o mesmo — e neste ano ganhou aprovação também para apneia obstrutiva do sono em pacientes obesos, reconhecendo a ligação entre peso e colapso das vias aéreas durante o sono.
Nos laboratórios, o horizonte se alarga ainda mais. Um estudo recente publicado na Nature Communications associou a semaglutida a uma redução de 50 a 56% na ocorrência e recorrência do transtorno por uso de álcool — resultado relevante num campo onde as opções medicamentosas sempre foram escassas. Pesquisadores da Universidade do Estado do Rio de Janeiro investigam se a tirzepatida pode reduzir a neuroinflamação ligada ao Alzheimer e a outros distúrbios cognitivos.
A liraglutida, outra droga da mesma família, já mostrou resultados concretos nessa direção: em estudo do Imperial College London, ela desacelerou a atrofia de regiões cerebrais ligadas à memória e à linguagem em quase 50%, e reduziu o declínio cognitivo em 18% ao longo de um ano em pacientes com Alzheimer inicial.
O que se desenha é uma revisão profunda de uma classe de medicamentos que o público conheceu como ferramenta estética. As moléculas GLP-1 — semaglutida, tirzepatida, liraglutida — parecem influenciar não apenas o apetite e o açúcar no sangue, mas também a inflamação e a capacidade do cérebro de se manter. O que começou como tratamento para obesidade se converte, gradualmente, em um conjunto de ferramentas para doenças metabólicas — e talvez para muito mais.
Brazil's health regulator has quietly expanded the role of weight-loss injectables far beyond their original purpose. Wegovy, the injectable pen that became synonymous with rapid weight loss, just won approval from the National Health Surveillance Agency (Anvisa) to treat a serious liver condition called metabolic dysfunction-associated fatty liver disease, or MASH. The approval applies to adults with moderate to advanced fibrosis who don't yet have cirrhosis—a meaningful distinction, since it opens the door to intervention before the damage becomes irreversible.
Wegovy is not alone in this expansion. Its chemical cousins have already carved out territory in other disease territories. Ozempic, which shares semaglutida as its active ingredient with Wegovy, has long been prescribed for type 2 diabetes. Mounjaro, built on a different molecule called tirzepatida, does the same work. This year, Mounjaro also gained approval for obstructive sleep apnea, the condition where people stop breathing repeatedly during sleep because their airways collapse. The approval carries a restriction: it applies only to people who are also obese, acknowledging that weight and airway obstruction are often intertwined.
What's happening in laboratories and research hospitals suggests the story is only beginning. Scientists are testing whether these drugs might help people struggling with alcohol use disorder, a condition that has historically been difficult to treat with medication. A recent study published in Nature Communications found that semaglutida was associated with a 50 to 56 percent reduction in both the initial occurrence and recurrence of alcohol use disorder compared to a control group. The finding is significant because treatment options for this condition remain limited, and a new class of medications could reshape how doctors approach the problem.
The research extends into neurodegenerative disease as well. Researchers at Rio de Janeiro State University are investigating whether tirzepatida might reduce neuroinflammation, the brain inflammation implicated in Alzheimer's and other cognitive disorders. Liraglutida, another drug in the same family, has already shown promise in this space. In a study conducted by Imperial College London, liraglutida slowed the shrinkage of brain regions responsible for memory, learning, language, and decision-making by nearly 50 percent in patients with early-stage Alzheimer's. Over the course of a year, it also slowed cognitive decline by 18 percent compared to patients who received a placebo.
These findings represent a fundamental shift in how we might think about a class of drugs that entered the public consciousness as a shortcut to thinness. The molecules themselves—semaglutida, tirzepatida, liraglutida—are synthetic versions of or mimics of GLP-1, a hormone that regulates appetite and blood sugar. It turns out that appetite and blood sugar are not the only systems these hormones touch. They appear to influence inflammation, neurological function, and the brain's ability to maintain itself. What began as a treatment for obesity is becoming a toolkit for metabolic disease, and possibly much more.
Citações Notáveis
Treatment options for alcohol use disorder remain limited, and a new class of medications could reshape how doctors approach the problem— Research findings on semaglutida and alcohol use disorder
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that Wegovy got approved for liver disease specifically, rather than just being used off-label?
Because approval means doctors can prescribe it with confidence, insurers might cover it, and we get real data on whether it works. Off-label use is a gray zone. Approval is a commitment.
The sleep apnea approval only works for obese patients. Why the restriction?
Because that's what the evidence showed. Sleep apnea in obese people often improves when they lose weight. The drug works partly by helping people lose weight. For non-obese sleep apnea, we don't know yet if it helps.
The alcohol use disorder finding seems almost accidental. How did researchers even think to test this?
GLP-1 affects reward pathways in the brain, not just appetite. Once you start looking at how a drug works at that level, you start asking what else it might touch. Addiction involves reward dysregulation. The connection wasn't crazy.
Is the Alzheimer's research solid, or is it early-stage hope?
It's real but preliminary. An 18 percent slowing of decline over a year is meaningful—it's not a cure, but it's not nothing. The brain shrinkage finding is even more interesting because it's a physical measure, not just a cognitive test. But we're talking about early-stage patients. We don't know if it works for everyone.
What's the risk of overselling these drugs?
People see weight loss and think the drug is magic. Then they hear about Alzheimer's and think it's a preventive. The truth is messier. These drugs help with specific conditions in specific populations. The hype can outrun the evidence.
What should someone actually take away from this?
That a drug developed for one problem sometimes solves others. That's how medicine works. But it also means we need to be patient and rigorous about which problems, in which people, and at what cost.